Brean Capital Reiterates Buy After Evoke Pharma (EVOK) Extends Interest-Payment-Only Period
Tweet Send to a Friend
Brean Capital reiterated a Buy rating and $13.00 price target on Evoke Pharma (NASDAQ: EVOK) after negotiating for its interest-payment-only ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
